Puma Biotechnology

December 19, 2016 - Puma Biotechnology to Move Stock Exchange Listing to Nasdaq
Ticker symbol to remain PBYI
Read

December 8, 2016 - Puma Biotechnology Presents Interim Results of Phase II CONTROL trial of PB272 in Extended Adjuvant treatment of HER2-Positive Early Stage Breast Cancer at the 2016 San Antonio Breast Cancer Symposium
Read

December 7, 2016 - Puma Biotechnology Presents Results of Biomarker Analysis of Phase II trial of PB272 in Neoadjuvant treatment of HER2-Positive Locally Advanced Breast Cancer at the 2016 San Antonio Breast Cancer Symposium
Read

December 7, 2016 - Puma Biotechnology Presents Interim Results of Phase II trial of PB272 for ERBB2 (HER2) Mutant, HER2 Non-Amplified, Metastatic Breast Cancer at the 2016 San Antonio Breast Cancer Symposium
Read

December 6, 2016 - Puma Biotechnology Initiates a Managed Access Program for PB272 (Neratinib) Outside the United States

Caligor Opco LLC to provide regulatory, logistical and supply chain support Read

November 14, 2016 - Puma Biotechnology Announces Presentations of Investigational Data at the San Antonio Breast Cancer Symposium (SABCS)
Read

November 9, 2016 - Puma Biotechnology Reports Third Quarter 2016 Financial Results
Read

October 31, 2016 - Puma Biotechnology to Present at Credit Suisse Healthcare Conference
Read

October 25, 2016 - Puma Biotechnology Closes $172 Million Public Offering of Common Stock
Read

October 21, 2016 - Puma Biotechnology Announces Underwriters’ Full Exercise of Option to Purchase Additional Share
Read

October 19, 2016 - Puma Biotechnology Prices Public Offering of Common Stock
Read

October 18, 2016 - Puma Biotechnology Announces Proposed Public Offering of Common Stock
Read

September 20, 2016 - Puma Biotechnology Announces U.S. FDA Acceptance of New Drug Application for PB272 (Neratinib) for Extended Adjuvant treatment of HER2-Positive Early Stage Breast Cancer
Read

August 22, 2016 - Puma Biotechnology Announces European Medicines Agency Validation of Marketing Authorization Application for PB272 (Neratinib) as Extended Adjuvant treatment of HER2-Positive Early Stage Breast Cancer in Europe
Read

August 9, 2016 - Puma Biotechnology Reports Second Quarter 2016 Financial Results
Read

July 21, 2016 - Puma Biotechnology Announces Interim 5-Year Disease Free Survival Data from Phase III trial of PB272 (Neratinib) in Extended Adjuvant HER2-Positive Early Stage Breast Cancer (ExteNET trial)
Read

July 21, 2016 - Puma Biotechnology Submits New Drug Application for PB272 (Neratinib) to U.S. FDA for Extended Adjuvant treatment of HER2-Positive Early Stage Breast Cancer
Read

July 7, 2016 - Puma Biotechnology Announces I-SPY 2 Phase II Study of Neratinib Published in The New England Journal of Medicine
Read

June 27, 2016 - Puma Biotechnology Submits Marketing Authorization Application for PB272 (Neratinib) as Extended Adjuvant treatment of HER2-Positive Early Stage Breast Cancer in Europe
Read

June 5, 2016 - Puma Biotechnology Presents Positive Phase II Data at the 2016 ASCO Annual Meeting
Read

May 18, 2016 - Puma Biotechnology Announces Publication of Neratinib Abstract for the 2016 ASCO Annual Meeting
Read

May 17, 2016 - Puma Biotechnology to Present at UBS Global Healthcare Conference
Read

May 10, 2016 - Puma Biotechnology Reports First Quarter 2016 Financial Results
Read

May 4, 2016 - Puma Biotechnology to Present at Bank of America Merrill Lynch Health Care Conference
Read

Apr. 20, 2016 - Puma Biotechnology’s Neratinib Featured in Poster Presentations at the AACR Annual Meeting 2016
Read

Apr. 14, 2016 - Puma Biotechnology’s NEfERT-T Phase II Study Published Online in JAMA Oncology
Read

Mar. 28, 2016 - Puma Biotechnology Updates Timeline for Filing New Drug Application NDA Filing Currently Anticipated Mid-2016
Read

Mar. 18, 2016 - Puma Biotechnology Announces Publication of Abstracts on Neratinib for the AACR Annual Meeting 2016
Read

Mar. 2, 2016 - Puma Biotechnology to Present at Cowen’s Health Care Conference
Read

Feb. 29, 2016 - Puma Biotechnology Reports Fourth Quarter and Full Year 2015 Financial Results
Read

Feb. 17, 2016 - Puma Biotechnology to Participate in Fireside Chat at RBC Capital Markets Global Healthcare Conference
Read

Feb. 16, 2016 - Puma Biotechnology Announces the Conclusion and Final Results of Eshelman’s Consent Solicitation
Read

Feb. 11, 2016 - Puma Biotechnology’s ExteNET Phase III Study Published Online in The Lancet Oncology
Read

Feb. 3, 2016 - Puma Biotechnology to Participate in Fireside Chat at Leerink Partners Global Healthcare Conference
Read

Jan. 8, 2016 - Puma Biotechnology Shareholders Overwhelmingly Reject Eshelman’s Consent Solicitation
Read

Jan. 4, 2016 - Puma Biotechnology to Present at J.P. Morgan Healthcare Conference
Read

2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011

2016 News Releases